More than hot flashes: Women raise awareness about menopause symptoms and work
The Mayo Clinic estimates that menopause symptoms lead to $1.8 billion in lost work time per year in the U.S. About 5% of ...
GlobalData on MSN6d
Genentech wins FDA approval for second stroke treatment
Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.
BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor ...
Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston
The new center will be a hub for both Roche and Genentech, bringing together expertise in Cardiovascular, Renal, and ...
FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...
The Harvard Crimson8h
Biotech Giant Roche Launches Innovation Center on Harvard’s Allston Research Campus
F. Hoffmann-La Roche, one of the world’s largest biotechnology companies, announced on Thursday that it will establish an ...
Fierce Biotech2d
Roche to house its CVRM research work at Harvard's new research campus
Roche and its Genentech subsidiary are planning to hitch up their cardiovascular, renal and metabolism R&D work and shift it over to a new center in Harvard’s Enterprise Research Campus. | Roche and ...
PMLive5d
Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke
Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in ...
GEN - Genetic Engineering and Biotechnology News2d
Roche Genentech Innovation Center Boston Launched at Harvard’s Enterprise Research Campus
The hub has also been created to strengthen an existing relationship between Harvard and Roche that has been in place for over a decade.
EMS12d
FDA approves clot-dissolving agent for treatment of acute ischemic stroke
TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...